Obesity Clinic to Launch at Hiyoshi Diabetes and Internal Medicine Clinic (Yokohama City) from May 2026 | Medical Treatment by Diabetes Specialists | Self-Pay Service Using Weekly Self-Injectable "Zepbound"
NQ Score
48/100
N1 Content Completeness
9
Key facts
- Obesity Clinic to Launch at Hiyoshi Diabetes and Internal Medicine Clinic (Yokohama City) from May 2026 | Medical Treatment by Diabetes Specialists | Self-Pay Service Using Weekly Self-Injectable "Zepbound"
- Starting May 2026, the Hiyoshi Diabetes and Internal Medicine Clinic in Yokohama, Kanagawa, will launch an obesity outpatient clinic led by diabetes specialists. The clinic will offer a self-pay treatment using "Zepbound," a once-weekly self-injectable drug officially approved for obesity. The treatment is available for individuals aged 18 and over with a BMI of 22 or higher, after confirming they do not have diabetes. This initiative aims to extend patients' overall healthy lifespan through appropriate, evidence-based obesity treatment, while avoiding the off-label use of diabetes medications, which has become a recent issue.
- Source: PR TIMES
- Date: Wed May 27 2026 10:30:02 GMT+0900 (Japan Standard Time)
Direct answer
Starting May 2026, the Hiyoshi Diabetes and Internal Medicine Clinic in Yokohama, Kanagawa, will launch an obesity outpatient clinic led by diabetes specialists. The clinic will offer a self-pay treatment using "Zepbound," a once-weekly self-injectable drug officially approved for obesity. The treatment is available for individuals aged 18 and over with a BMI of 22 or higher, after confirming they do not have diabetes. This initiative aims to extend patients' overall healthy lifespan through appropriate, evidence-based obesity treatment, while avoiding the off-label use of diabetes medications, which has become a recent issue.
- Citation
- Obesity Clinic to Launch at Hiyoshi Diabetes and Internal Medicine Clinic (Yokohama City) from May 2026 | Medical Treatment by Diabetes Specialists | Self-Pay Service Using Weekly Self-Injectable "Zepbound" (Wed May 27 2026 10:30:02 GMT+0900 (Japan Standard Time)), PR TIMES
- Source
- PR TIMES
- Date
- Wed May 27 2026 10:30:02 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
Starting May 2026, the Hiyoshi Diabetes and Internal Medicine Clinic in Yokohama, Kanagawa, will launch an obesity outpatient clinic led by diabetes specialists. The clinic will offer a self-pay treatment using "Zepbound," a once-weekly self-injectable drug officially approved for obesity. The treatment is available for individuals aged 18 and over with a BMI of 22 or higher, after confirming they do not have diabetes. This initiative aims to extend patients' overall healthy lifespan through appropriate, evidence-based obesity treatment, while avoiding the off-label use of diabetes medications, which has become a recent issue.
AI Analysis
Frequently Asked Questions
- Q: Is Hiyoshi Diabetes and Internal Medicine Clinic close to Hiyoshi Station?
- A: Yes, the Hiyoshi Diabetes and Internal Medicine Clinic is located in Hiyoshi-honcho, Kohoku-ku, Yokohama, and is conveniently accessible from Hiyoshi Station. Please check the clinic's website for detailed access information.
- Q: Are there other clinics in Kohoku-ku, Yokohama that prescribe Zepbound?
- A: As Zepbound is a relatively newly approved drug, the number of medical institutions that can prescribe it is limited. Hiyoshi Diabetes and Internal Medicine Clinic specializes in this treatment as an obesity outpatient service managed by diabetes specialists.
- Q: How can I book an appointment for this obesity outpatient service?
- A: For booking methods, please visit the official website of Hiyoshi Diabetes and Internal Medicine Clinic or contact them directly by phone.
- Q: What is the first step to receive the treatment?
- A: First, you need to visit the clinic and undergo a blood test to check for diabetes and its complications. Only those who are diagnosed as not having diabetes are eligible for the self-pay treatment.
- Q: Why is this treatment a self-pay service?
- A: Under the current Japanese health insurance system, treatments for obesity using drugs like Zepbound are not covered by insurance unless specific conditions are met, hence it is offered as a self-pay service.